Arrowhead pharmaceuticals presents preclinical data on aro-alk7 for treatment of obesity

Pasadena, calif.--(business wire)---- $arwr--arrowhead pharmaceuticals, inc. (nasdaq: arwr) today announced preclinical results on aro-alk7, the company's investigational rna interference (rnai) therapeutic targeting activin receptor-like kinase 7 (alk7) being developed as a potential treatment for obesity. the results were presented in a poster at the keystone symposia on obesity and adipose tissue held february 23–26, 2025 in banff, ab, canada. aro-alk7 is the first rnai-based therapy to directly targe.
ALK Ratings Summary
ALK Quant Ranking